KI-1126 (Kuhnil Pharmaceutical)

KI-1126 is a small molecule drug candidate being developed by Kuhnil Pharmaceuticals for the treatment of comorbid hyperlipidemia and hypertension. Currently in the preclinical stage of development, it is part of Kuhnil's pipeline of cardiovascular and metabolic disease treatments. As a combination or multi-target approach, it aims to address two major risk factors for cardiovascular disease simultaneously. While the specific active pharmaceutical ingredients and molecular targets have not been publicly disclosed, the project reflects the developer's focus on fixed-dose combinations and multi-indication therapies for chronic metabolic conditions.

Brand names

Duowell A